News

This is a 5-year follow-up for the COMBI trials, which treated patients with unresectable or metastatic melanoma with dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor). Interim analyses have been published and all have shown significant overall and progression-free survivals. This study provides a critical follow-up point for combination BRAFi + MEKi, although the main […]

Xpovio (selinexor) tablets have been approved for use in combination with dexamethasone to treat adults with relapsed refractory multiple myeloma, the U.S. Food and Drug Administration announced last week. The drug combination was granted accelerated approval for patients whose disease remains resistant to other treatments, including at least two proteasome inhibitors, at least two immunomodulatory

To assess the incidence of BCR-ABL kinase domain (KD) mutation detection and its prognostic significance in chronic phase chronic myeloid leukemia (CP-CML) patients treated with tyrosine kinase inhibitors (TKIs). We analyzed characteristics and outcome of 253 CP-CML patients who had at least one mutation analysis performed using direct sequencing. Of them, 187 patients were early

Patients with stage IV non–small-cell lung cancer (NSCLC) and BRAF V600 mutations may benefit from targeted therapies. The French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study was a national prospective cohort study aiming to describe the molecular characteristics and clinical outcome of all consecutive NSCLC patients screened for molecular alterations 83 cases with BRAF mutant

The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemoimmunotherapy for many patients. However, individually, they rarely lead to eradication of measurable residual disease (MRD) and usually are taken indefinitely or until progression. We

Numerous studies have evaluated the role of PI3K inhibitors in breast cancer, some with positive results but an excess toxicity profile. The SOLAR-1 trial is the first to show a clinically meaningful benefit (PFS nearly doubled) with the addition of alpelisib in patients who harbor a PIK3CA mutation. Although very few patients on this study

The wide heterogeneity in multiple myeloma (MM) outcome is driven mainly by cytogenetic abnormalities. The current definition of high-risk profile is restrictive and oversimplified. To adapt MM treatment to risk, we need to better define a cytogenetic risk classification. To address this issue, we simultaneously examined the prognostic impact of del(17p); t(4;14); del(1p32); 1q21 gain;

In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations. We report an updated OS and tolerability

The authors recommend that breast surgeons, genetic counselors, and medical professionals knowledgeable in genetic testing offer patient education and counseling, make recommendations for genetic testing, and arrange testing for their patients. All patients with a personal history of breast cancer should be offered genetic testing, including BRCA1/2 and PALB2. Patients who have already undergone testing

ERBB2 (HER2) amplification is an emerging biomarker in colon cancer, conferring sensitivity to combination anti-HER2 therapy. Measurement of HER2 copy number is typically performed using surgical specimens, but cell-free circulating tumor DNA (ctDNA) analysis may be a noninvasive alternative. We determined the sensitivity of plasma copy number (pCN) for detecting ERBB2 amplifications and whether pCN